Company: RCUS
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001724521-25-000040
Chunk: 156

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 8
Chunk 156
---
Other comprehensive loss—— — (6)(6)Net loss—— (267)— (267)Balance at December 31, 202272.91,206 (542)(7)657 Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 15, Stockholders' Equity)1.225 — — 25 Issuance of common stock in connection with our equity award programs1.47 — — 7 Stock-based compensation— 73 —— 73 Other comprehensive income—— — 7 7 Net loss—— (307)— (307)Balance at December 31, 202375.51,311 (849)— 462 Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 15, Stockholders' Equity)15.2228 — — 228 Issuance of common stock in connection with our equity award programs1.52 — — 2 Stock-based compensation—76 — — 76 Net loss—— (283)— (283)Balance at December 31, 202492.2$1,617 $(1,132)$— $485 

See accompanying notes.

77

ARCUS BIOSCIENCES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

Year Ended December 31,202420232022Cash flow from operating activitiesNet loss$(283)$(307)$(267)Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Stock-based compensation expense76 73 65 Depreciation and amortization10 8 6 Noncash lease expense7 8 8 Impairment on right-of use assets20 — — Amortization of discounts on marketable securities(25)(19)— Other items, net3 2 3 Changes in operating assets and liabilities:Receivable from collaboration partners ($14, $19 and $704 from a related party)28 15 704 Other assets ($6, ($4) and ($2) from a related party)22 (14)2 Accounts payable3 (1)8 Deferred revenue (($56), ($77) and ($107) to a related party)(56)(68)(112)Other liabilities